Acesyra Fractional CO₂ Laser & RF Microneedling System

The Acesyra Fractional CO₂ Laser & RF Microneedling System (Model L300) is a dual-technology platform that integrates a 10,600 nm fractional CO₂ laser with 1 MHz RF microneedling in a single device — making it a true combination platform system. **What makes it different:** Rather than choosing between CO2 resurfacing and RF microneedling, practitioners can sequence both modalities within a single treatment plan or alternate between them based on the patient's skin condition. The 12.1" LCD touchscreen interface provides an intuitive clinical workflow. This platform type suits clinics wanting to offer both ablative resurfacing and non-ablative collagen stimulation from one investment. **Confidence: Moderate** — Platform architecture is confirmed. The product data includes detailed specs (500 VA rated power, 12.1" touchscreen, English/Chinese UI). No explicit FDA clearance data is present in the product record.

The Acesyra platform's dual-modality design allows differentiated treatment protocols: **CO₂ laser module:** - Skin resurfacing / wrinkle reduction: 1–3 sessions, 4–6 week intervals - Scar revision: 3–5 sessions, 6–8 week intervals - Typical downtime: 5–10 days (fractional mode reduces this vs. fully ablative) **RF Microneedling module:** - Skin rejuvenation / tightening: 3–4 sessions, 4–6 week intervals - Acne scars / stretch marks: 4–6 sessions, 4–6 week intervals - Typical downtime: 1–3 days (mild erythema, swelling) **Confidence: Moderate** — Protocol follows standard clinical practice for each modality. **Critical flag for procurement: confirm FDA clearance status for both the CO₂ and RF microneedling modules. FDA 510(k) clearance has not been documented in the product record (fda_key field is empty). Request the manufacturer's regulatory documentation for both modules before marketing as FDA cleared.**

The Acesyra FDA status **cannot be confirmed from current product data** — the fda_key field is empty and no FDA clearance claim is present in the what_it_is or lede fields. **Confidence: Low** — No FDA clearance is documented. **This is the highest-priority procurement flag: the Acesyra should not be marketed as FDA cleared until regulatory documentation is provided and verified. Request the manufacturer's 510(k) clearance letter or evidence of FDA registration. If cleared only in China or CE-marked only, note this distinction clearly for international buyers.**